Lenvatinib and pembrolizumab combination in recurrent endometrial cancer: regional experience

Abstract

Introduction. Over the past ten years, the incidence and mortality rates of endometrial cancer in Russia have remained quite high. Chemotherapy shows limited effectiveness in the case of recurrence, necessitating the search for new treatment methods, such as immune-targeted therapy. The combination of pembrolizumab and lenvatinib has demonstrated significant improvements in survival rates, changing the treatment standards for patients with recurrent uterine cancer.

Objective. To evaluate the efficacy and safety of the combination of lenvatinib + pembrolizumab in patients with recurrent endometrial cancer, analyze our own experience with this therapy, and compare it with international data.

Materials and Methods. The study included 39 cases of the combination of pembrolizumab + lenvatinib administered to patients with recurrent endometrial cancer. Patients with ECOG status 0–1 and microsatellite stable tumors were included.

Results. Treatment with the combination of pembrolizumab and lenvatinib achieved control over the tumor process in 95 % of patients. The most common side effects were arterial hypertension and hand-foot syndrome; however, through dose adjustments and symptomatic therapy, it was possible to manage these adverse events effectively.